On Air Now

Current Show

The Mark Levin Show   5:00 PM - 8:00 PM

Call The Mark Levin Show at 1-877-381-3811

Show Info »

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 550 AM Wausau, WI 99.9 FM Stevens Point, WI

Weather

Current Conditions(Wausau,WI 54403)

More Weather »
72° Feels Like: 72°
Wind: W 6 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Isolated Thunderstorms 56°

Tomorrow

PM Thunderstorms 80°

Fri Night

Thunderstorms Early 55°

GlaxoSmithKline diabetes drug faces U.S. approval delay

The GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor
The GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor

LONDON (Reuters) - U.S. regulators have pushed back an approval decision on GlaxoSmithKline's experimental diabetes drug albiglutide by three months until April 15, 2014, Britain's biggest drugmaker said on Friday.

A separate filing for the drug in Europe is progressing on schedule.

The once-weekly treatment for type 2 diabetes belongs to the same class of injectable GLP-1 drugs as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca.

Based on reported clinical trial results, industry analysts have questioned how well albiglutide will fare in a crowded market - especially with a promising new rival in the pipeline in the form of Eli Lilly's dulaglutide.

(Reporting by Ben Hirschler; Editing by Keith Weir)

Comments